FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Deep learning algorithm-based multimodal MRI radiomics and pathomics data improve prediction of bone metastases in primary prostate cancer. PMID 38316655 · J Cancer Res Clin Oncol · 2024-Feb-05 Study is a randomized diagnostic/prognostic model development trial for predicting bone metastases in prostate cancer. It is not a randomized controlled trial of a drug intervention with a time-to-event efficacy endpoint. The primary outcome is diagnostic performance (AUC), not survival or progression. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group. PMID 38315268 · J Patient Rep Outcomes · 2024-Feb-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparison of the efficacy and tolerability of elobixibat plus sodium picosulfate with magnesium citrate and split-dose 2-L polyethylene glycol with ascorbic acid for bowel preparation before outpatient colonoscopy: a study protocol for the multicentre, randomised, controlled E-PLUS trial. PMID 38310266 · BMC Gastroenterol · 2024-Feb-03 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET. PMID 38310262 · BMC Cancer · 2024-Feb-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Transperitoneal vs retroperitoneal laparoscopic radical nephrectomy: a double-arm, parallel-group randomized clinical trial. PMID 38310213 · BMC Urol · 2024-Feb-03 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol. PMID 38308321 · Trials · 2024-Feb-03 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro). PMID 38308227 · BMC Cancer · 2024-Feb-03 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Perioperative treatment with tranexamic acid in melanoma (PRIME): protocol for a Danish multicentre randomised controlled trial investigating the prognostic and treatment-related impact of the plasminogen-plasmin pathway. PMID 38309757 · BMJ Open · 2024-Feb-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of aquatic exercise program versus on-land exercise program on cancer-related fatigue, neuropathy, activity and participation, quality of life, and return to work for cancer patients: study protocol for a randomized controlled trial. PMID 38308248 · BMC Complement Med Ther · 2024-Feb-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. PMID 37758193 · Neuro Oncol · 2024-Feb-02 Study is a randomized, prospective, pilot (Phase II-like) trial evaluating safety and immunological response, not efficacy with time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial. PMID 38212068 · J Nucl Med · 2024-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial. PMID 38153755 · JAMA Oncol · 2024-Feb-01 The trial is a randomized, open-label, multicenter, Phase II/III trial with time-to-event primary endpoint (cumulative incidence of severe chronic GVHD, reported with HR). However, the intervention is mesenchymal stem cells (MSCs), which are a cell-based therapy, not a conventional drug. The trial explicitly lacks a Phase III designation (the title mentions 'Phase II/III', but the abstract does not confirm it is Phase III; the trial registration is ChiCTR-IIR-16007806, which is an interventional study, but the abstract does not specify the phase as Phase III). The intervention is non-drug-only (MSCs are cellular therapy, not a pharmacological agent). Therefore, the report is excluded due to lack of Phase III evidence and drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Erratum: Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. PMID 38113437 · J Clin Oncol · 2024-Feb-01 The record is an erratum for a Phase III trial but does not contain original result data or time-to-event efficacy endpoint information (OS, PFS, HR, KM) required for inclusion. The abstract is empty, and the publication type ('Published Erratum') indicates it is not a primary or final result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review. PMID 38095885 · JAMA Oncol · 2024-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. PMID 38095878 · JAMA Oncol · 2024-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer: A Randomized Clinical Trial. PMID 38060250 · JAMA Oncol · 2024-Feb-01 The study is a randomized clinical trial in advanced lung cancer patients with survival as a time-to-event outcome. However, the intervention is non-drug (exercise-based), and eligibility requires a drug-containing intervention. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PROLONGED MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME. PMID 38010051 · Shock · 2024-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. PMID 37991778 · JAMA Oncol · 2024-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial. PMID 37939105 · Clin Cancer Res · 2024-Feb-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. PMID 37931185 · J Clin Oncol · 2024-Feb-01 The record reports overall survival (secondary endpoint) from the STIC CTC trial, a randomized trial in advanced breast cancer comparing CTC-count-driven therapy (endocrine therapy or chemotherapy) versus investigator choice. The trial is described as randomized and includes drug interventions. While the specific phase is not explicitly stated in the provided metadata, the trial design and reporting (comparing two active treatment strategies in advanced cancer) are consistent with a definitive Phase III trial. The result is an original report of a planned secondary endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Anterior Quadratus Lumborum Block at Lateral Supra-Arcuate Ligament vs Lateral Quadratus Lumborum Block for Postoperative Analgesia after Laparoscopic Colorectal Surgery: A Randomized Controlled Trial. PMID 37861219 · J Am Coll Surg · 2024-Feb-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy. PMID 37652304 · Int J Radiat Oncol Biol Phys · 2024-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis. PMID 37611260 · Hepatology · 2024-Feb-01 While the study involves oncology outcomes (HCC incidence), is human, randomized, includes a drug intervention, and reports time-to-event results, the explicit trial phase is not established as Phase III/IIIb or Phase II/III. The abstract describes an 'extension study on a randomized controlled trial' but does not specify the original trial phase, making phase3_or_definitive criteria unclear. The report_type is 'other' as it is an extension study analysis, not a primary report of a definitive-phase trial with a primary oncology efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nationwide use and Outcome of Minimally Invasive Distal Pancreatectomy in IDEAL Stage IV following a Training Program and Randomized Trial. PMID 37139822 · Ann Surg · 2024-Feb-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Superior Sensibility after Full Breast Reconstruction with Autologous Fat Transfer. PMID 37114918 · Plast Reconstr Surg · 2024-Feb-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Cardio-oncology disparities: Interplay of psychosocial stress, inflammation, and cardiometabolic health among Black breast cancer survivors. PMID 38510748 · Am Heart J Plus · 2024-Feb This is a protocol for a pilot, randomized, non-pharmacological intervention study. It lacks results, is not a Phase III/IIIb or Phase II/III trial, and does not have a time-to-event primary/key secondary efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. PMID 38460451 · J Therm Biol · 2024-Feb The study is an oncology Phase III trial with a primary result, but it is excluded because (1) the intervention lacks a drug component, (2) the primary endpoint is not a time-to-event outcome, and (3) randomization is not established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial. PMID 38427931 · JCO Precis Oncol · 2024-Feb This is a secondary, biomarker-focused analysis from a randomized trial. While it involves a drug (palbociclib) and reports Kaplan-Meier PFS analysis, it is not the primary or key secondary efficacy report of the trial, and the trial phase (III/IIIb or II/III) is not explicitly established in the provided metadata. Therefore, it does not meet the criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Concurrent Use of Crocin During Chemoradiation for Esophageal Squamous Cell Carcinoma. PMID 38385429 · Cancer Invest · 2024-Feb The trial is a randomized controlled trial in oncology with a drug intervention (crocin) and original results. However, it is not a Phase III/IIIb or Phase II/III trial (phase not specified in metadata, but primary endpoints are pathological response and toxicity, not a time-to-event efficacy endpoint). The primary efficacy endpoints are pathological response and toxicity; survival analysis is listed as a secondary endpoint, but the abstract does not provide any results, Kaplan-Meier curves, or hazard ratios for this endpoint, so time-to-event cannot be established. Therefore, it does not meet the eligibility criteria for a definitive time-to-event efficacy report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. PMID 38324085 · Invest New Drugs · 2024-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer. PMID 38320486 · NEJM Evid · 2024-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Chemotherapy With UFT/LV Versus UFT/LV Plus PSK in Stage II/III Colorectal Cancer. PMID 38307591 · Anticancer Res · 2024-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis. PMID 38301482 · EBioMedicine · 2024-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Predicting survival in patients with buccal cancer: A study based on SEER database and external validation in China. PMID 38284829 · Cancer Med · 2024-Feb The study is a prognostic nomogram development and validation study using observational SEER database data and a single-center retrospective cohort. It is not a randomized trial comparing a drug-containing intervention. The 'randomized' tag in publication types refers to random data splitting for model training/validation, not randomization of treatment arms. No drug intervention is tested. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma. PMID 38274490 · JHEP Rep · 2024-Feb This is a meta-analysis and real-world cohort study, not an original formal-result report from a single randomized trial. While it analyzes Phase III trials and time-to-event data, it does not present the primary results of a single trial eligible for digitization. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized controlled trial of a tailored navigation intervention to promote breast and cervical cancer screening among intergenerational Southeast Asian women. PMID 38234710 · Contemp Clin Trials Commun · 2024-Feb The record describes a protocol for a randomized trial of a non-drug (navigation/information) intervention to improve cancer screening rates. It does not report results of a Phase II/III or III/IIIb randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A nomogram to preoperatively predict the aggressiveness of non-functional pancreatic neuroendocrine tumors based on CT features. PMID 38232572 · Eur J Radiol · 2024-Feb Study is a retrospective analysis developing a prognostic nomogram for pancreatic neuroendocrine tumors. While it includes random splitting of patients into training/validation sets and reports time-to-event outcomes, it does not involve a drug-containing intervention or represent a Phase III/IIIb or Phase II/III randomized trial of a therapeutic agent. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. PMID 38224701 · Lancet Oncol · 2024-Feb The trial is a randomized, phase 3, oncology study with a drug intervention and original results. However, the primary endpoint is 'complete control' (a categorical, symptom-based efficacy measure at 120 hours), not a time-to-event outcome such as overall survival, progression-free survival, or any other survival metric. No time-to-event analysis (e.g., Kaplan-Meier, hazard ratio) is reported. Therefore, it does not meet the cohort's requirement for a primary or key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non-small-cell lung cancer who have progressed after anti-PD-1/L1 therapy. PMID 38214075 · Cancer Med · 2024-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A protocol for a randomized trial evaluating the role of carbon-ion radiation therapy plus camrelizumab for patients with locoregionally recurrent nasopharyngeal carcinoma. PMID 38205914 · Cancer Med · 2024-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life. PMID 38193250 · Palliat Med · 2024-Feb The trial is a cluster-randomised oncology trial with a drug intervention, but the primary endpoint is not a time-to-event efficacy endpoint. Median survival is mentioned but is not the primary/key secondary endpoint of the study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. PMID 38167937 · Nat Med · 2024-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial. PMID 38159337 · Eur J Cancer · 2024-Feb The study is a Phase Ib, non-randomized trial. It does not meet the required criteria of being a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Should we remove wine from the Mediterranean diet?: a narrative review. PMID 38157987 · Am J Clin Nutr · 2024-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202. PMID 38157649 · Eur J Surg Oncol · 2024-Feb The report is an exploratory subset analysis from JCOG1202 (a phase III trial) examining feasibility and toxicity after major hepatectomy, not the primary efficacy results. It lacks any reported time-to-event efficacy endpoints (OS, PFS, DFS, etc.) for the overall trial population, which is required for inclusion. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effect of Mortality alongside 5-Year Survival Rates and Incidence on the Public's Perceived Benefits of Cancer Screening and Screening Intention: A Web-Based Experimental Study. PMID 38156617 · Med Decis Making · 2024-Feb The study is a randomized experiment on cancer screening communication, not a drug intervention trial. It lacks a drug-containing intervention, a Phase III/IIIb or Phase II/III trial context, and a clinical trial time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. PMID 38154393 · Eur J Cancer · 2024-Feb The study is a Phase IIIb, single-arm, open-label trial. While it reports on time-to-event efficacy endpoints (PFS, OS) for a drug combination, the lack of randomization is a core exclusion criterion for the specified cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial. PMID 38142708 · Lancet Diabetes Endocrinol · 2024-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. PMID 38142695 · Lancet Haematol · 2024-Feb The study is a randomized, double-blind, phase 3 trial of a drug intervention in an oncology context (HSCT recipients). However, the primary efficacy endpoint is the proportion of participants developing clinically significant CMV infection (a binary outcome) by week 28, not a time-to-event endpoint such as overall survival or progression-free survival. No Kaplan-Meier analysis or hazard ratio is reported for the primary efficacy endpoint. Therefore, it does not meet the inclusion criteria for a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial. PMID 38141879 · Radiother Oncol · 2024-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |